Mabuchi Seiji, Sugiyama Toru, Kimura Tadashi
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
J Gynecol Oncol. 2016 May;27(3):e31. doi: 10.3802/jgo.2016.27.e31.
Clear cell carcinoma (CCC) of the ovary is known to show poorer sensitivity to chemotherapeutic agents and to be associated with a worse prognosis than the more common serous adenocarcinoma or endometrioid adenocarcinoma. To improve the survival of patients with ovarian CCC, the deeper understanding of the mechanism of CCC carcinogenesis as well as the efforts to develop novel treatment strategies in the setting of both front-line treatment and salvage treatment for recurrent disease are needed. In this presentation, we first summarize the mechanism responsible for carcinogenesis. Then, we highlight the promising therapeutic targets in ovarian CCC and provide information on the novel agents which inhibit these molecular targets. Moreover, we discuss on the cytotoxic anti-cancer agents that can be best combined with targeted agents in the treatment of ovarian CCC.
已知卵巢透明细胞癌（CCC）对化疗药物的敏感性较差，且与较常见的浆液性腺癌或子宫内膜样腺癌相比，其预后更差。为提高卵巢CCC患者的生存率，需要更深入地了解CCC的致癌机制，并努力开发针对一线治疗和复发性疾病挽救治疗的新型治疗策略。在本报告中，我们首先总结致癌机制。然后，我们重点介绍卵巢CCC中有前景的治疗靶点，并提供抑制这些分子靶点的新型药物信息。此外，我们还讨论了在卵巢CCC治疗中可与靶向药物最佳联合使用的细胞毒性抗癌药物。
